# A Bioequivalence Study of Sunitinib Malate Capsules.

> **NCT05800106** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Sunitinib malate capsules generic product
- **DRUG:** Sunitinib malate capsules reference product

## Key facts

- **NCT ID:** NCT05800106
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-04
- **Primary completion:** 2019-01-06
- **Final completion:** 2019-01-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05800106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05800106, "A Bioequivalence Study of Sunitinib Malate Capsules.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05800106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*